MedWatch

Majority owner: Lundbeck's new share structure could double acquisition power

A new proposed split share structure could give Lundbeck’s majority shareholder, the Lundbeck Foundation, the option to maintain influence while enabling billion-dollar investment hunts. Consequently, the pharmaceutical firm’s acquisition capacity could be doubled, the foundation’s CEO says.

Lene Skole, CEO of the Lundbeck Foundation | Photo: Gregers Tycho/ERH

Should Lundbeck succeed in adopting a new share structure dividing shares into two categories, the pharmaceutical company could gain the option to go on billion-dollar external financing hunts without the Lundbeck Foundation, majority shareholder, having to relinquish any power.

Lene Skole, CEO of the Lundbeck Foundation, welcomes the proposal, which came on Wednesday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs